SG11201803080YA - Compositions and methods for immune-mediated cancer therapy - Google Patents

Compositions and methods for immune-mediated cancer therapy

Info

Publication number
SG11201803080YA
SG11201803080YA SG11201803080YA SG11201803080YA SG11201803080YA SG 11201803080Y A SG11201803080Y A SG 11201803080YA SG 11201803080Y A SG11201803080Y A SG 11201803080YA SG 11201803080Y A SG11201803080Y A SG 11201803080YA SG 11201803080Y A SG11201803080Y A SG 11201803080YA
Authority
SG
Singapore
Prior art keywords
immune
compositions
methods
cancer therapy
mediated cancer
Prior art date
Application number
SG11201803080YA
Other languages
English (en)
Inventor
Ruey-Min Lee
Original Assignee
Teclison Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teclison Ltd filed Critical Teclison Ltd
Publication of SG11201803080YA publication Critical patent/SG11201803080YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201803080YA 2015-10-21 2016-10-21 Compositions and methods for immune-mediated cancer therapy SG11201803080YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562244457P 2015-10-21 2015-10-21
PCT/US2016/058303 WO2017070606A1 (en) 2015-10-21 2016-10-21 Compositions and methods for immune-mediated cancer therapy

Publications (1)

Publication Number Publication Date
SG11201803080YA true SG11201803080YA (en) 2018-05-30

Family

ID=58558217

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803080YA SG11201803080YA (en) 2015-10-21 2016-10-21 Compositions and methods for immune-mediated cancer therapy

Country Status (12)

Country Link
US (2) US11534445B2 (zh)
EP (1) EP3365015A4 (zh)
JP (3) JP2018531277A (zh)
KR (1) KR20180086195A (zh)
CN (2) CN108472366B (zh)
AU (2) AU2016342039B2 (zh)
BR (1) BR112018007889A2 (zh)
CA (1) CA3002381A1 (zh)
HK (1) HK1251490A1 (zh)
IL (2) IL258701B1 (zh)
SG (1) SG11201803080YA (zh)
WO (1) WO2017070606A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472366B (zh) 2015-10-21 2023-03-17 泰克利森有限公司 用于免疫介导的癌症疗法的组合物和方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
DE60038624T2 (de) 1999-10-07 2009-06-10 Aquilar-Cordova, Carlos, Estuardo, Newton Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
NZ563281A (en) * 2002-05-17 2009-05-31 Celgene Corp Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
CN102026634B (zh) * 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
DE102008002395A1 (de) * 2008-06-12 2009-12-17 Biotronik Vi Patent Ag Wirkstoffbeladenes Implantat
WO2015035112A1 (en) * 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
US20150273033A1 (en) * 2013-11-05 2015-10-01 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
US20170035864A1 (en) * 2013-12-09 2017-02-09 Bullet Biotechnology, Inc. SPECIFIC VIRUS-LIKE PARTICLE-CpG OLIGONUCLEOTIDE VACCINES AND USES THEREOF
EP3209321B1 (en) * 2014-10-21 2021-06-23 SciClone Pharmaceuticals International Ltd. Treatment of cancer with immune stimulators
US10973822B2 (en) * 2015-07-02 2021-04-13 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
CN108472366B (zh) 2015-10-21 2023-03-17 泰克利森有限公司 用于免疫介导的癌症疗法的组合物和方法

Also Published As

Publication number Publication date
CN108472366A (zh) 2018-08-31
CN108472366B (zh) 2023-03-17
IL309273A (en) 2024-02-01
EP3365015A1 (en) 2018-08-29
EP3365015A4 (en) 2019-07-24
HK1251490A1 (zh) 2019-02-01
JP7476450B2 (ja) 2024-05-01
JP2022044827A (ja) 2022-03-17
US11534445B2 (en) 2022-12-27
AU2023202294A1 (en) 2023-05-11
WO2017070606A1 (en) 2017-04-27
AU2016342039B2 (en) 2023-03-09
JP2024019699A (ja) 2024-02-09
CA3002381A1 (en) 2017-04-27
KR20180086195A (ko) 2018-07-30
IL258701A (en) 2018-06-28
AU2016342039A1 (en) 2018-05-10
US20230133566A1 (en) 2023-05-04
US20190070186A1 (en) 2019-03-07
BR112018007889A2 (pt) 2018-10-30
JP2018531277A (ja) 2018-10-25
IL258701B1 (en) 2024-03-01
CN116196427A (zh) 2023-06-02

Similar Documents

Publication Publication Date Title
IL267247B (en) Compositions and methods for treating cancer
IL258688A (en) Compositions and methods for cancer viral neoepitopes
IL304820A (en) Preparations and methods for the treatment of cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
PT3377516T (pt) Composição para o tratamento do cancro
HK1247630A1 (zh) 用於增强癌症治療的效果的組合物和方法
IL265786A (en) Materials and methods for increasing radiotherapy against cancer
EP3331612A4 (en) METHOD AND COMPOSITIONS FOR TUMOR THERAPY
HUE054673T2 (hu) Rák kezelésére szolgáló eljárások és készítmények
IL256523A (en) Compositions and methods for treating cancer
IL271326A (en) Compositions and methods for enhancing radiotherapy in cancer
EP3347025A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL246607B (en) Improved cellular preparations and methods for cancer treatment
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
IL255638A (en) Compositions and methods for treating cancer
EP3169333A4 (en) Methods and compositions for enhancing cancer therapy
EP3548070A4 (en) METHODS AND COMPOSITIONS FOR ANTI-CANCER THERAPY
ZA201707024B (en) Cancer treatment composition
HK1251490A1 (zh) 用於免疫介導的癌症治療的組合物和方法
EP3268028A4 (en) Compositions and methods for treating cancer
HK1250958A1 (zh) 用於治療癌症的組合物和方法
IL274866A (en) Preparations and methods for the treatment of cancer
AU2022231657A1 (en) Compositions and Methods for Treating Cancer